Skip Nav Destination
Issues
1 November 2007
-
Cover Image
Cover Image
Intermolecular interactions of 17β-estradiol (E2) with estrogen receptor α (ERα), of metribolone (R1881) with androgen receptor (AR), and of 17-hydroexemestane with both of these receptors. The X-ray crystal structures of E2 (gray) and R1881 (gray) co-complexed with ERα (1GWR at 2.4 Å resolution) and AR (1XQ3 at 2.25 Å resolution), respectively, were superimposed with in silico modeled E2 (yellow) and R1881 (yellow) docked to their cognate receptors, and compared to modeled 17-hydroexemestane (yellow) docked to ERα and AR. Hydrogen, oxygen, and nitrogen atoms are shown in cyan, red, and blue, respectively. The carbon backbone of the protein is shown in green. Hydrogens from the X-ray crystal conformations of E2 and R1881 were omitted. H-bonds were shown to the modeled compound conformations only. Intermolecular H-bonds up to 3.5 Å are shown as black dashed lines and their length in angstroms indicated. 17-Hydroexemestane interacted with ERα as a very low affinity ligand, and with AR as a high affinity ligand, through conserved recognition motifs. For details, see Ariazi et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Research Articles: Therapeutics, Targets, and Development
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Eric A. Ariazi; Andrei Leitão; Tudor I. Oprea; Bin Chen; Teresa Louis; Anne Marie Bertucci; Catherine G.N. Sharma; Shaun D. Gill; Helen R. Kim; Heather A. Shupp; Jennifer R. Pyle; Alexis Madrack; Anne L. Donato; Dong Cheng; James R. Paige; V. Craig Jordan
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics
Lee-Yee Choong; Simin Lim; Marie Chiew-Shia Loh; Xiaohui Man; Yunhao Chen; Weiyi Toy; Mengfei Pan; Chien-Shing Chen; Anuradha Poonepalli; M. Prakash Hande; Puay-Hoon Tan; Manuel Salto-Tellez; Chow-Yin Wong; Nilesh Shah; Brian J. Druker; Yoon-Pin Lim
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
Christian Moser; Sven A. Lang; Silvia Kainz; Andreas Gaumann; Stefan Fichtner-Feigl; Gudrun E. Koehl; Hans J. Schlitt; Edward K. Geissler; Oliver Stoeltzing
Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells
Angela Sutton; Veronique Friand; Dulce Papy-Garcia; Maylis Dagouassat; Loïc Martin; Roger Vassy; Oualid Haddad; Odile Sainte-Catherine; Michel Kraemer; Line Saffar; Gerard Yves Perret; Jose Courty; Liliane Gattegno; Nathalie Charnaux
Conjugation of an anti–transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells
Tracy R. Daniels; Patrick P. Ng; Tracie Delgado; Maureen R. Lynch; Gary Schiller; Gustavo Helguera; Manuel L. Penichet
Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines
Lourdes Toral-Barza; Wei-Guo Zhang; Xinyi Huang; Leonard A. McDonald; Edward J. Salaski; Laurel R. Barbieri; Wei-Dong Ding; Girija Krishnamurthy; Yong Bo Hu; Judy Lucas; Valerie S. Bernan; Ping Cai; Jeremy I. Levin; Tarek S. Mansour; James J. Gibbons; Robert T. Abraham; Ker Yu
Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation
Metin Kurtoglu; Ningguo Gao; Jie Shang; Johnathan C. Maher; Mark A. Lehrman; Medhi Wangpaichitr; Niramol Savaraj; Andrew N. Lane; Theodore J. Lampidis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.